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and human-to-human virus transmis-
sion leaves areas for further work.
These results support previous 
ﬁ   ndings that knowledge about avian 
inﬂ  uenza, especially about prevention 
and human-to-human transmission, has 
scope for improvement (4,5). Persons 
in Europe reported that they have little 
ability to prevent themselves from get-
ting avian inﬂ  uenza (6). Previous re-
search in the Lao People’s Democratic 
Republic examined how consumers’ 
knowledge of avian inﬂ  uenza risk re-
duced the likelihood that consumers 
will substitute poultry for other foods 
during an avian inﬂ  uenza crisis. This 
research indicates the importance of 
informing persons about consumption 
and transmission-related risks to re-
duce the likelihood of unnecessary be-
havioral changes that can cause larger 
macrolevel market effects (7).
The state of knowledge about 
avian inﬂ  uenza in Europe during the 
outbreak in the spring of 2006 leaves 
room for further public health infor-
mation campaign efforts, especially 
those that increase consumers’ under-
standing of consumption-related avian 
inﬂ  uenza risks. Persons in Europe ap-
pear to be aware of culling procedures 
and the risks of touching infected birds 
but have a more limited understanding 
of how avian inﬂ  uenza in their region 
should inﬂ   uence their consumption 
patterns.
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Human Salmonella 
Infection Yielding 
CTX-M β-Lactamase, 
United States
To the Editor: In the United 
States most third-generation cepha-
losporin resistance among salmonel-
lae is due to AmpC plasmid–mediated 
β-lactamases. Extended-spectrum 
β-lactamases (ESBLs) have rare-
ly been reported (1). The CTX-M 
β-lactamases constitute a group of 
ESBL enzymes that are increasing in 
prevalence worldwide. Currently, the 
CTX-M enzymes are classiﬁ  ed  into 
5 different subgroups on the basis of 
DNA sequence similarities (2). We re-
port on a domestically acquired CTX-
M –producing  Salmonella isolate in 
the United States.
In 2003, public health laborato-
ries in all US state health departments 
submitted every 20th non-Typhi Sal-
monella (NTS) isolate from humans 
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Table. Knowledge of human risks associated with avian influenza, European region, 2006* 
For each of the following statements tell me whether, in your opinion, it is true or false: 
Response, no. (%) 
Transmission risks  True False Don’t know 
  The avian influenza virus can be transmitted between humans  9,864 (33.8)  16,574 (56.8)  2,732 (9.4) 
  Humans can catch avian influenza by touching contaminated birds  22,722 (77.9)  4,473 (15.3)  1,975 (6.8) 
Food-related risks
  Even when it is contaminated, poultry is not a health risk if it is cooked  17,906 (61.4)  8,536 (29.3)  2,728 (9.4) 
  The avian influenza virus contained in an egg or present on its shell can 
  be eliminated by prolonged cooking 
17,369 (59.5)  6,593 (22.6)  5,208 (17.9) 
  It is not dangerous to eat the meat of a chicken vaccinated against avian 
 influenza 
12,833 (44.0)  9,272 (31.8)  7,065 (24.2) 
Other
  The vaccination against seasonal influenza is also effective against avian 
 influenza 
4,265 (14.6)  20,847 (71.5)  4,058 (13.9) 
  If a chicken is contaminated by avian influenza on a farm, all the poultry  
  on that farm must be destroyed immediately 
24,492 (84.0)  2,725 (9.3)  1,953 (6.7) 
*Source: Eurobarometer 65.2 (http://ec.europa.eu/public_opinion/archives/eb/eb65/eb65_ee_exec.pdf). Information in boldface refers to the correct 
answer. LETTERS
to the Centers for Disease Control 
and Prevention (CDC) for suscepti-
bility testing by the National Antimi-
crobial Resistance Monitoring System 
(NARMS). MICs were determined by 
broth microdilution and interpreted 
according to Clinical and Laboratory 
Standards Institute standards (www.
clsi.org), when available. Resistance 
to cefquinome was deﬁ  ned  as  >32 
mg/L.
Among the 1,864 human NTS 
isolates submitted to NARMS in 2003, 
105 (5.6%) displayed elevated MICs 
(>2 mg/L) to ceftriaxone or ceftio-
fur, third-generation cephalosporins 
used in human and veterinary medi-
cine, respectively. Genomic DNA was 
prepared from the 105 isolates, and a 
PCR with degenerate primers capa-
ble of detecting all CTX-M enzymes 
identiﬁ  ed a single positive S. enterica 
ser. Typhimurium (3). The isolate 
came from a stool sample collected 
in September 2003 from a white, non-
Hispanic, US-born, 3-month-old boy 
who lived in the state of Georgia. The 
patient had diarrhea and fever for ≈1 
week. Because neither the patient nor 
his family had traveled internationally 
in the 3 months before specimen col-
lection, the infection appears to have 
been domestically acquired. The pa-
tient did not receive any antimicrobial 
agents before illness but was treated 
for 14 days with cefpodoxime. The in-
fant recovered from the illness without 
complications.
The isolate displayed resistance 
to β-lactams, aminoglycosides, pheni-
cols, tetracyclines, and folate pathway 
inhibitors (Table). Two β-lactamases 
(isoelectric pH [pI] 7.5 and 8.8) were 
resolved by isoelectric focusing.
Group-speciﬁ  c PCR primers were 
used to characterize the presumed 
blaCTX-M gene (4). Primers TOHO1–
2F and TOHO1–1R yielded a 351-
bp product, conﬁ   rming a group II 
blaCTX-M gene. To perform sequencing 
of the entire gene, a ClustalW align-
ment with representatives from group 
II was performed to identify primers 
(DNASTAR, Madison, WI, USA). The 
sequence of the gene was identical to 
the sequence of the blaCTX-M-5 gene de-
tected in other isolates of S. enterica 
ser. Typhimurium (GenBank acces-
sion nos. U95364 and AF286192) as 
well as to the kluA-2 gene of Kluyvera 
ascorbata (GenBank accession no. 
AJ251722).
The genetic environment of the 
blaCTX-M-5 gene was investigated by 
PCR speciﬁ   c for upstream insertion 
elements (ISEcp1, IS26, and ORF513) 
and the downstream sequence sul1 (5). 
Ampliﬁ  cation with primer ISEcp1 and 
an internal blaCTX-M-5 primer yielded a 
PCR product of ≈350 bp. Sequencing 
conﬁ  rmed presence of the 3′ end in-
verted repeat region of the ISEcp1.
Presence of other β-lactamase–
encoding genes (blaTEM,  blaSHV, and 
blaOXA) was investigated by PCR 
(6–8). Ampliﬁ   cation with primers 
OXA-1F and OXA-1R yielded a 595-
bp product with a sequence consistent 
with that of blaOXA-1 (8).
To determine whether the CTX-M 
enzyme was plasmid-borne, plasmids 
were extracted and transformed into 
electrocompetent  Escherichia coli 
DH10B. The transformant exhibited 
resistance to cefotaxime but not to 
ceftazidime (Table). In addition, the 
transformant exhibited resistance to 
cefquinome and cefepime. The pres-
ence of a blaCTX-M gene was conﬁ  rmed 
by PCR (3,4). The blaOXA gene could 
not be ampliﬁ  ed from the E. coli trans-
formant (8).
A CTX-M–producing Salmonella 
isolate has been reported only once 
previously in the United States (9). 
This was in 1994, when an isolate of 
Salmonella ser. Typhimurium var. Co-
penhagen with a CTX-M-5 was recov-
ered from a 4-month-old girl adopted 
from Russia; that infection was not 
domestically acquired (9). We com-
pared the 1994 isolate and the isolate 
in this study by pulsed-ﬁ  eld gel elec-
trophoresis; the isolates showed dis-
tinct patterns.
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Table. MIC values of antimicrobial drugs for the Salmonella ser. Typhimurium isolate 
and its Escherichia coli DH10B transformant 
MIC, mg/L
Antimicrobial agent
S. ser. 
Typhimurium
E. coli DH10B 
transformant
E. coli
DH10B
Amikacin 1 1 1
Amoxicillin–clavulanic acid 32 16 4
Ampicillin >32 >32 4
Aztreonam 32 32 0.12
Cefepime 32 32 <0.06
Cefotaxime >64 >64 <0.06
Cefotaxime–clavulanic acid 0.25 0.12 <0.06
Cefoxitin 2 8 8
Cefquinome >32 >32 <0.06
Ceftazidime 8 8 0.5
Ceftazidime–clavulanic acid 0.5 0.25 0.12
Ceftiofur >8 >8 0.5
Ceftriaxone >64 >64 <0.25
Chloramphenicol >32 <2< 2
Ciprofloxacin <0.016 <0.016 <0.016
Gentamicin 4 <0.25 <0.25
Imipenem 0.5 0.25 0.25
Kanamycin >64 <8< 8
Nalidixic acid 4 1 1
Piperacillin-tazobactam >64 2 2
Streptomycin <32 >64 >64
Sulfisoxazole >256 <16 <16
Tetracycline >32 <4< 4
Trimethoprim-sulfamethoxazole >4 <0.12 <0.12LETTERS
The ISEcp1 insertion sequence 
has been described as a ﬂ  anking re-
gion of several blaCTX-M genes and has 
been implicated in the expression and 
mobilization of the genes (5). A recent 
study by Lartigue et al. showed that a 
CTX-M-2 progenitor in K. ascorbata 
could be mobilized and transferred to 
a conjugative E. coli plasmid by the 
ISEcp1B element; enhanced mobiliza-
tion was observed in the presence of 
ceftazidime, cefotaxime, and pipera-
cillin (10).
This  Salmonella isolate’s resis-
tance to cefepime and cefquinome, 
fourth-generation cephalosporins, is 
troubling. Cefquinome is not approved 
for use in the United States but has 
been used in Europe for treating food 
animals since 1994. ESBLs, including 
CTX-M enzymes, are more common 
in Europe than in the United States 
(1). Further studies are warranted to 
clarify the extent to which the use of 
cefquinome has contributed to high 
CTX-M prevalence in Europe.
In conclusion, we report a do-
mestically acquired CTX-M–produc-
ing Salmonella isolate in the United 
States. Because third-generation ce-
phalosporins are important for treating 
invasive  Salmonella infections, con-
tinued monitoring of ESBL-producing 
bacteria is important.
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Yersinia 
pseudotuberculosis 
O:1 Traced to Raw 
Carrots, Finland 
To the Editor: Illness caused by 
Yersinia pseudotuberculosis is main-
ly characterized by fever and acute 
abdominal pain due to mesenteric 
lymphadenitis that mimics appendici-
tis. Secondary manifestations include 
erythema nodosum and reactive arthri-
tis (1). Outbreaks have been reported 
in the Northern Hemisphere, includ-
ing Canada (2,3), Japan (4), and Rus-
sia (5). Several community outbreaks 
have also been reported in Finland 
since 1982 (1,6–9). Only in a few of 
the outbreaks has the vector or source 
of the infection been identiﬁ  ed. Re-
cently, fresh produce, such as iceberg 
lettuce (7) and carrots (9), has been 
implicated by epidemiologic inves-
tigations as a source of infection, but 
mechanisms of contamination of fresh 
produce have remained unknown.
On April 8, 2004, the National 
Public Health Institute of Finland was 
informed of several cases of gastroen-
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